We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys Provides an Update on its Proprietary Development Portfolio

News   Sep 10, 2015

 
MorphoSys Provides an Update on its Proprietary Development Portfolio
 
 
Advertisement
 

RELATED ARTICLES

Industrial-Scale Farming May Be Perpetuating Spread of Antibiotic Resistant Staphs Through Pigs and People

News

According to a study, multidrug-resistant Staphylococcus aureus strains are spreading between pigs, farmworkers, their families and community residents, which could represent an emerging public health threat.

READ MORE

NIH Closes Enrolment for Two Sub-Studies in ACTIV-3 Trial

News

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrolment in two sub-studies. The first sub-study was examining the investigational monoclonal antibody therapy VIR-7831 and the second was evaluating a combined monoclonal antibody therapy containing BRII-196 and BRII-198.

READ MORE

Probing the Proteomic Landscape of Cancer To Discover Drug Targets

News

Researchers have shown that analysis of the proteomics, or all the protein data, from aggressive human cancers is a valuable strategy to identify potential novel therapeutic targets.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE